Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTION Trial: Adoptive Cellular Therapy Following Dose-Intensified Temozolomide in Newly-diagnosed Pediatric High-grade Gliomas
NCT03334305Phase 1Terminated
- Sponsor
- University of Florida
- Start
- Aug 2018
- Primary completion
- Mar 2025
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines, RNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of TTRNA-DC vaccine and TTRNA-xALT in high-grade glioma (HGG) (2 arms), sponsored by University of Florida. Primary endpoint: Safety of TTRNA-DCs and TTRNA-xALT up to 10 months. Started Aug 2018; status: terminated.
02
Drugs
TTRNA-DC vaccineTTRNA-xALT
03
Conditions
high-grade glioma (HGG)
Beyond the preview
Go deeper on NCT03334305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03334305.